Healthcare / Medical DevicesStockholm
$19.65
+0.50 (+2.60%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-187.5M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$372M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-54.0%
↓Gross Margin
-15.3%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.6%
FCF CAGR
—
FCF margin
-1528.9%
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $11.1M · net income $-182.5M · FCF $-169.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $11.1M | $11.1M | $2.4M | $4.4M | $12.8M |
| Net Income | $-182.5M | $-182.5M | $-216.9M | $-229.4M | $-268.7M |
| EBITDA | $-161.0M | $-161.0M | $-196.0M | $-211.0M | $-252.7M |
| EPS | -27.40 | -27.40 | -1.86 | -492.38 | -1301.69 |
| Gross Margin | -15.3% | -15.3% | -470.5% | 22.4% | -167.2% |
| Operating Margin | -1584.3% | -1584.3% | -9046.4% | -5196.7% | -2055.6% |
| Net Margin | -1644.3% | -1644.3% | -9181.7% | -5165.9% | -2101.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | -5.51 | 0.11 | 0.13 |
| Current Ratio | 10.48 | 10.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-169.7M | $-169.7M | $-187.5M | $-236.9M | $-268.1M |
| Returns | |||||
| ROE | -54.0% | -54.0% | 789.9% | -121.0% | -164.7% |
| Valuation | |||||
| P/B | 387.19 | 387.19 | — | 1.26 | 1.81 |
| Growth & Yield | |||||
| Revenue Growth | 369.9% | 369.9% | -46.8% | -65.3% | — |
| EPS Growth | -1373.1% | -1373.1% | 99.6% | 62.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-56.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.86 → -27.40
Residual
-56.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.